Nowadays, it seems established that ITCs are well known to target Keap1 for activating Nrf2 pathway resulting in induction of gene expression of antioxidant and Phase II detoxifying enzymes [46,51–54] by means of which they provide numerous health benefits including chemoprevention [55], neuroprotection [56], alleviation of obesity and insulin resistance [57]. The gene discussed is NFE2L2; the disease is obesity due to melanocortin 4 receptor deficiency.